{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Impact of Tumor-Infiltrating B Cells in Lung Adenocarcinoma

Activity Steps

1 Activity
2 Take Test 3Certificate

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify a type of cancer in which tumor-infiltrating B cells affect patient responses to immunotherapy.
  2. Summarize results from research revealing the spatial landscape of tumor-infiltrating B cells and plasma cells in early-stage lung adenocarcinoma (LUAD).

Learning Outcomes

Seventy-five percent of participants will demonstrate knowledge of tumor-infiltrating B cells and plasma cells in cancers, particularly in lung adenocarcinoma, by achieving a minimum score of 70% on the outcomes-based posttest.

Disclosures

All authors, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.

Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH
  • NM - BON 1.0 CH
  • SC - BON 1.0 CH
  • WV - BOERN 1.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.













Planner
Test Code: OT0123
Published: January 2023
Expires: 12/5/2025
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Lindsey Nolen
Categories: Cancer , Lung Disease , Oncology
Specialties: Oncology
Topics: Cancer , Lung